Oleander Medical Technologies was founded with the mission to innovate revolutionary cancer treatments, focusing on combating the most invasive and deadly types. The company's core product, Targeted Osmotic Lysis (TOL), leverages the unique properties of malignant cancer cells to selectively destroy them. By exploiting how sodium channels in these cells respond to disease, Oleander aims to provide a highly effective and targeted cancer treatment. Their market focus is on developing cutting-edge medical technologies that offer new hope for patients with aggressive cancers.

Key figures affiliated with Oleander Medical Technologies include Dr. Dennis Paul and Dr. Harry Gould from Louisiana State University, whose research on cell function and sodium channels underpins the TOL technology. The company has garnered attention for its innovative approach, although specific investors and detailed achievements have not been disclosed. Oleander's impact lies in its potential to transform cancer treatment paradigms, offering a novel solution that could significantly improve patient outcomes for some of the most challenging cancer types.